Question Bank › Counterparties stepping up before the numbers do

Counterparties stepping up before the numbers do

Counterparties stepping up before the numbers do: escalating committed demand the reported results don't yet show

Calls Tested
492
Answered YES
16
Hit Rate
3.3%
rare by design

OPKO Health, Inc. (OPK) — this company's answers

NO on the Q1 2022 call 2022-05-09 D
The model's full reasoning — Q1 2022 call → NOWe need answer only YES or NO. Need evaluate transcript. Need determine if management describes counterparties currently stepping up commitment beyond prior level, and results don't yet reflect because contribution only beginning ahead. We need parse call. OPKO Health Q1 2022. Topics: ModeX acquisition, BioReference, Sema4, Pfizer milestones. Need identify paying counterparties escalation. Possible candidates: - Pfizer launched Neglina in Germany/Japan, triggered $85M milestones. But that's milestone payment, not ongoing step-up? Management says Pfizer launched in major markets, continuing with FDA. Milestone payments received Q2. Is that counterparty stepping up? It's a partner launching product, but not described as "committed to larger volumes" beyond prior? Maybe launch triggers milestones, but not future revenue? They haven't forecasted royalty/gross profit share until history. So no. - Sema4 acquisition of GeneDx: counterparty? Sema4 paid $150M and shares, potential $150M earnout. But that's divestiture, not customer commitment. - BioReference: core clinical base volume increased 4% vs Q4, driven by preferred status with UnitedHealthcare and Aetna. Preferred status with Aetna effective Jan 1. This is a payer relationship moving to higher level? They say "commercial payer interactions continue to be successful with our preferred status with Aetna, which became effective on the 1st of this year. Volume in our clinical base business increased 4% versus the fourth quarter, driven by our preferred status with UnitedHealthcare and Aetna." This is a step-up? Preferred status means more patients? But is it "currently stepping up" and results not reflect? They mention volume increased 4% already. Not necessarily "numbers lag" with most ahead. They don't say reported results don't reflect. They say volume increased. So no. - Scarlet Health: launched, services available, receiving reimbursement from payers for over 85 million patients. New relationships with Teladoc, MVP Healthcare. Teladoc formal relationship, Scarlet now offered by Teladoc. This is new business won, deliveries beginning? Is it a step-up? They say "I am proud to announce today a formal relationship with Teladoc... Scarlet is now offered by Teladoc Health as part of their new whole person health care experience." Also MVP collaboration. This is new counterparties committing.

← Back to the full OPK analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management describe that the counterparties who pay the company — customers, clients, partners, distributors, payers, or program sponsors — are CURRENTLY STEPPING UP their commitment to the company in a way that goes clearly beyond their prior level of business, AND does management convey that the reported results do not yet meaningfully reflect that step-up, because its contribution is only beginning and mostly still ahead? Answer YES when management's own words convey BOTH halves as one coherent, present-tense story, in whatever form fits the business: (1) A REAL ESCALATION BY PAYING COUNTERPARTIES, ALREADY HAPPENING OR ALREADY COMMITTED. Management describes counterparties moving to a distinctly higher level of engagement than they had before — not merely strong demand in the usual pattern. This may take whatever form fits the industry, for example: customers who started small now committing to substantially larger volumes, broader deployments, more sites, or wider scope; a counterparty moving a relationship from an initial phase into a much bigger committed phase; orders, bookings, or committed work arriving at a scale or pace beyond what the company had been receiving; buyers committing earlier, longer, or bigger than this business has been used to; or new business already won whose delivery ramps ahead. What matters is that the escalation is described as actually occurring or actually committed now — real orders, signed expansions, deliveries beginning, ramps underway — grounded in the behavior of identifiable paying counterparties, not in pipeline, interest, market size, or management's own hopes. (2) THE NUMBERS LAG THE ESCALATION, AND MANAGEMENT SAYS SO. Management conveys, directly or plainly in substance, that the results just reported still mostly reflect the business before this step-up — for example, the larger commitments have only begun converting into revenue, the ramp is early with most delivery ahead, or the company is now preparing, hiring, or building to serve committed business that has not yet flowed through the reported period — so today's numbers understate the business the counterparties have already committed to. Answer NO if the call describes only strong demand, growth, or a good quarter in the company's ordinary rhythm, without counterparties visibly moving to a higher level of commitment than before. NO if the step-up is only hoped for, in negotiation, in pipeline, or dependent on decisions, approvals, or financing not yet obtained. NO if the escalation is a single routine order or renewal of normal size for this business. NO if the increased activity is attributed mainly to a temporary spike, catch-up, pull-forward, or one-time event that management expects to fade. NO if the escalated business is already fully reflected in the reported results with nothing meaningful still to convert. NO if management is chiefly explaining delays, cancellations, or problems with a previously described ramp. NO if the idea appears only in an analyst's question or model that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
SCPH scPharmaceuticals Inc. Q3 2023 2023-11-08 B
GVP GSE Systems, Inc. Q1 2023 2023-05-15 D
OEC Orion Engineered Carbons S.A. Q4 2022 2023-02-17 B+
EVGO EVgo, Inc. Q2 2022 2022-08-09 C+
SYM Symbotic Inc. Q3 2022 2022-08-01 B+
VNRX VolitionRx Limited Q1 2022 2022-05-12 F
FAT FAT Brands Inc. Q4 2021 2022-03-21 F
FLUX Flux Power Holdings, Inc. Q2 2022 2022-02-10 D
OOMA Ooma, Inc. Q3 2022 2021-12-02 B+
GFS GLOBALFOUNDRIES Inc. Q3 2021 2021-11-30 A
KOP Koppers Holdings Inc. Q2 2018 2018-08-12 C+
PRIM Primoris Services Corporation Q2 2018 2018-08-11 C+
MKC McCormick & Company, Incorporated Q2 2018 2018-06-28 C+
ILMN Illumina, Inc. Q1 2018 2018-04-24 A
LIND Lindblad Expeditions Holdings, Inc. Q2 2017 2017-08-06 C
GOGO Gogo Inc. Q1 2016 2016-05-06 C+

How the model reasoned

KOP · Q2 2018 → YESThe question is: Does management describe that counterparties (customers etc.) are CURRENTLY STEPPING UP their commitment beyond prior levels, AND that reported results do not yet meaningfully reflect...**NO** The transcript does not describe any counterparties (customers, clients, partners, etc.) currently stepping up their commitment to a distinctly higher level of engagement beyond prior patterns in a way that is already occurring or committed now, with the reported results lagging because most of the benefit is still ahead. The closest item is the major box store converting its ground-contact treated wood program to Koppers’ patented MicroPro technology, planned for late fall with “little effect on the balance of 2018” and a “nice boost heading into 2019.
SCPH · Q3 2023 → YESThe question is: Does management describe that counterparties who pay the company are CURRENTLY STEPPING UP their commitment beyond prior levels, AND that the reported results do not yet meaningfully ...YES The transcript shows management describing a clear escalation in payer commitments: a new unrestricted-access agreement with the largest closed IDN (over 8 million lives, fixed copay) and preferred formulary status with a major government retiree payer (adding 1.1 million lives). They explicitly note that direct IDN purchases were not meaningful in Q3 but will be “a meaningful part of our business” moving forward, especially in 2024, and that the new payer decisions “could positively impact FUROSCIX co-pays as early as the fourth quarter.
GFS · Q3 2021 → YESThe question is: Does management describe that counterparties (customers) are CURRENTLY STEPPING UP their commitment beyond prior levels, AND that the reported results do not yet meaningfully reflect ...**YES** Management describes counterparties (customers) stepping up their commitment through new and expanded long-term agreements (LTAs) and prepayments/access fees, which have grown since the roadshow (from ~$2.5B to north of $3B, with additional $500M+ added post-roadshow) and now exceed $20B in forward revenues. This is framed as real escalation in committed business, with customers signing more agreements and prepaying for future capacity. The reported Q3 results ($1.7B revenue, $0.07 adjusted EPS) and Q4 guidance ($1.

More from the question bank

Escape velocity out of a small baseCash cost of the waitPromise already turning into factMomentum handoff to a young engineCustomers coming back on their ownScheduled future in administrationAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.